Three Cannabinoids, Three Completely Different Pharmacologies — Why THC, CBD, and THCV Don't Work the Same Way
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee's 2008 review demolished the assumption that plant cannabinoids are pharmacologically interchangeable — showing that THC is a partial agonist, CBD is an antagonist, and THCV switches between blocking and activating receptors depending on dose.
For decades, the working assumption was simple: cannabinoids are cannabinoids. They come from the same plant, they hit the same receptors, they vary in potency. THC is the strong one. CBD is the mild one. The rest are background noise.
In 2008, Roger Pertwee — the same pharmacologist who had chronicled the field's 66-year history two years earlier — published a review that demolished that assumption. He showed that three major plant cannabinoids don't just differ in potency. They have completely different, sometimes opposite, pharmacological profiles at the very same receptors.
One activates. One blocks. One does both, depending on the dose.
Same plant. Three different drugs.
Three Molecules, Three Personalities
This three-way comparison is the core insight of the paper — and it has implications for everything from product labeling to drug safety to why different cannabis preparations feel so different.
THC: The Partial Agonist
THC is the molecule everyone knows — the psychoactive component of cannabis, isolated by Mechoulam in 1964. But Pertwee's characterization added a critical nuance: THC is a partial agonist at CB1, not a full one.
What does that mean? A full agonist activates a receptor to its maximum capacity. A partial agonist activates it only partway — there's a ceiling on how much activation is possible, no matter how much of the drug you take. THC can never fully activate CB1. It gets you high, but there's a built-in limit.
This matters for two reasons:
The partial agonist profile also explains tolerance. As chronic THC exposure causes CB1 receptors to downregulate and desensitize, a partial agonist loses efficacy faster than a full agonist would — because it was already operating below maximum. This is why regular cannabis users need increasingly more THC to achieve the same effect, and why tolerance breaks work: the receptors recover, and partial agonism becomes effective again.
CBD: The Unexpected Blocker
Here's what most people get wrong about CBD:
Myth vs. Reality
CBD activates cannabinoid receptors more gently than THC — it's a milder version of the same thing.
CBD does not activate CB1 or CB2 receptors. It blocks them. Pertwee showed that CBD acts as an antagonist at both receptors with unexpectedly high potency. Later research refined this to 'negative allosteric modulator' — CBD binds a different site on the receptor and reduces THC's ability to activate it.
The Evidence
In cell lines and tissue preparations expressing CB1 or CB2 receptors, CBD displaced cannabinoid agonists and reduced their functional effects. Laprairie et al. (2015) demonstrated that CBD binds an allosteric site on CB1, reducing the potency and efficacy of both THC and 2-AG on downstream signaling (PLCβ3, ERK1/2). CBD also prevents CB1 receptor internalization by reducing β-arrestin2 recruitment.
Pertwee (2008), Br J Pharmacol; Laprairie et al. (2015), PMC4621983
This is why CBD doesn't get you high. It's not a weaker version of THC — it's pharmacologically opposite at cannabinoid receptors. And it's why adding CBD to THC changes the experience: CBD literally reduces THC's ability to activate CB1.
But CBD isn't pharmacologically empty just because it doesn't activate cannabinoid receptors. It's one of the most polyvalent molecules in pharmacology, hitting multiple non-cannabinoid targets:
This multi-target profile — not cannabinoid receptor activation — is how CBD produces its therapeutic effects. It's also why CBD pharmacology is so hard to study: the effects come from at least five different receptor systems acting simultaneously.
For the practical question of how CBD and THC differ, this paper provides the definitive receptor-level explanation.
THCV: The Shapeshifter
The most pharmacologically surprising cannabinoid in the review is THCV — delta-9-tetrahydrocannabivarin. Structurally similar to THC (a propyl side chain instead of pentyl), THCV does something no other well-characterized cannabinoid does: it switches between antagonist and agonist depending on dose.
At low doses, THCV blocks CB1 — acting as an antagonist that suppresses appetite and is non-psychoactive. At high doses, it flips and activates CB1 — potentially producing mild psychoactive effects and appetite stimulation. At CB2, it's consistently a partial agonist regardless of dose.
This unique pharmacology has made THCV the most therapeutically interesting of the minor cannabinoids:
- Appetite suppression via CB1 antagonism — without the psychiatric side effects that killed rimonabant (because THCV is a neutral antagonist, not an inverse agonist)
- Improved glucose metabolism — a 2016 clinical trial showed THCV significantly decreased fasting plasma glucose and improved β-cell function in Type 2 diabetes patients
- Non-psychoactive at therapeutic doses — the antagonist range
The popular nickname "diet weed" undersells the pharmacology. THCV isn't just THC that doesn't make you hungry. It's a fundamentally different molecule at the receptor level.
Why One Plant Makes Three Different Drugs
Understanding these three pharmacological profiles explains almost every practical question about cannabis:
Why does CBD change the THC high? Because CBD blocks the receptor THC activates. Adding CBD to THC literally reduces THC's ability to bind and activate CB1. This is why high-CBD strains feel different from high-THC strains — it's receptor-level competition.
Why does tolerance develop? THC is a partial agonist — already operating below maximum receptor activation. When chronic use causes CB1 downregulation, a partial agonist loses its effect faster than a full agonist would. The gap between what THC can activate and what the remaining receptors allow narrows until the drug barely works.
Why are synthetic cannabinoids (K2/Spice) so dangerous? They're full agonists — no ceiling on receptor activation. Plant THC's partial agonism is a built-in safety mechanism. Remove that ceiling with a synthetic full agonist, and you get seizures, psychosis, and death.
Why do different THC:CBD ratios feel so different? Because the ratio determines the balance between activation (THC) and blockade (CBD) at the same receptor. A 1:1 product produces a different pharmacological profile than a 20:1 product — not just in degree, but in kind.
Why are THCV products marketed for weight management? Because at typical oral doses, THCV acts as a CB1 antagonist — suppressing the same appetite-stimulating pathway that THC activates. Same receptor, opposite effect, depending on which molecule gets there.
Frequently Asked Questions
Cite this study
Pertwee, R G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.. British journal of pharmacology, 153(2), 199-215. https://doi.org/10.1038/sj.bjp.0707442